Press Releases
Samsung Biologics hosts 13th Annual General Meeting of Shareholders
Samsung Biologics hosted its 13th Annual General Meeting of Shareholders.
Shareholders approved all agenda items as proposed, including financial statements and the appointment of an independent director and audit committee member.
“Despite macroeconomic uncertainties, Samsung Biologics posted record revenue in 2023 and was recognized for its sustainable management from multiple global institutions,” said John Rim, CEO and President of Samsung Biologics. “We ask for continued support and trust as we are committed to maintaining our positive growth trajectory, both organically and inorganically, to maximize client and shareholder excellence.”
Samsung Biologics’ Plant 4, the world’s largest single plant, is nearing full utilization from expanded partnerships with global pharma companies, while the company is currently securing orders for a fifth plant which will be operational by April 2025. Samsung Biologics is expected to maintain its lead in biomanufacturing capacity with 784,000 liters upon the completion of Plant 5.
The company is also building a standalone ADC facility to expand its services portfolio, to be operational by the end of 2024. By leveraging its proven expertise in antibody engineering and manufacturing, Samsung Biologics aims to provide end-to-end ADC services with the launch of the new facility. The company also recently signed an ADC partnership deal with LegoChem Biosciences, and via the Life Science fund, invested in biotech companies with pioneering ADC technologies, including Araris Biotech and AimedBio.
Detailed information on the Annual General Meeting is available here.
Samsung Biologics hosted its 13th Annual General Meeting of Shareholders.
Shareholders approved all agenda items as proposed, including financial statements and the appointment of an independent director and audit committee member.
“Despite macroeconomic uncertainties, Samsung Biologics posted record revenue in 2023 and was recognized for its sustainable management from multiple global institutions,” said John Rim, CEO and President of Samsung Biologics. “We ask for continued support and trust as we are committed to maintaining our positive growth trajectory, both organically and inorganically, to maximize client and shareholder excellence.”
Samsung Biologics’ Plant 4, the world’s largest single plant, is nearing full utilization from expanded partnerships with global pharma companies, while the company is currently securing orders for a fifth plant which will be operational by April 2025. Samsung Biologics is expected to maintain its lead in biomanufacturing capacity with 784,000 liters upon the completion of Plant 5.
The company is also building a standalone ADC facility to expand its services portfolio, to be operational by the end of 2024. By leveraging its proven expertise in antibody engineering and manufacturing, Samsung Biologics aims to provide end-to-end ADC services with the launch of the new facility. The company also recently signed an ADC partnership deal with LegoChem Biosciences, and via the Life Science fund, invested in biotech companies with pioneering ADC technologies, including Araris Biotech and AimedBio.
Detailed information on the Annual General Meeting is available here.